BeiGene, Ltd.
BeiGene, Ltd. (BGNE) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for BeiGene, Ltd. (BGNE), covering cash flow, earnings, and balance sheets.
BeiGene, Ltd. (BGNE) Income Statement & Financial Overview
Explore comprehensive income reports for BeiGene, Ltd. BGNE, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.13B | $1.002B | $929.17M | $751.65M |
| Cost of Revenue | $160.56M | $170.46M | $138.13M | $124.94M |
| Gross Profit | $967.26M | $831.14M | $791.03M | $626.72M |
| Gross Profit Ratio | $0.86 | $0.83 | $0.85 | $0.83 |
| R&D Expenses | $542.01M | $496.18M | $454.47M | $460.64M |
| SG&A Expenses | $504.68M | $455.22M | $443.73M | $427.43M |
| Operating Expenses | $1.05B | $951.40M | $898.20M | $888.07M |
| Total Costs & Expenses | $1.21B | $1.12B | $1.04B | $1.01B |
| Interest Income | $7.81M | $10.64M | $13.22M | $16.16M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $50.25M | $71.29M | $24.11M | $25.29M |
| EBITDA | -$29.18M | -$48.97M | -$83.05M | -$236.06M |
| EBITDA Ratio | -$0.03 | -$0.05 | -$0.09 | -$0.31 |
| Operating Income | -$79.42M | -$120.27M | -$107.16M | -$261.35M |
| Operating Income Ratio | -$0.07 | -$0.12 | -$0.12 | -$0.35 |
| Other Income/Expenses (Net) | -$5.93M | $21.96M | $1.24M | $17.92M |
| Income Before Tax | -$85.35M | -$98.30M | -$105.92M | -$243.43M |
| Income Before Tax Ratio | -$0.08 | -$0.10 | -$0.11 | -$0.32 |
| Income Tax Expense | $66.53M | $23.05M | $14.48M | $7.72M |
| Net Income | -$151.88M | -$121.35M | -$120.41M | -$251.15M |
| Net Income Ratio | -$0.13 | -$0.12 | -$0.13 | -$0.33 |
| EPS | -$0.11 | -$0.09 | -$0.09 | -$0.19 |
| Diluted EPS | -$0.11 | -$0.09 | -$0.09 | -$0.19 |
| Weighted Avg Shares Outstanding | $1.36B | $1.36B | $1.36B | $1.36B |
| Weighted Avg Shares Outstanding (Diluted) | $1.36B | $1.36B | $1.36B | $1.36B |
Over the last four quarters, BeiGene, Ltd.'s revenue moved from $751.65M in Q1 2024 to $1.13B in Q4 2024. Operating income in Q4 2024 was -$79.42M, with a strong operating margin of -7%. Despite fluctuations in R&D and SG&A expenses, EBITDA for BeiGene, Ltd. remained robust at -$29.18M, reflecting operational efficiency. Net income dropped to -$151.88M, with an EPS of -$0.11. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan